ROCHE CUP MX39795

This study will compare the efficacy and safety of molecularly-guided therapy versus standard platinum-containing chemotherapy in participants with cancer of unknown primary site (CUP; non-specific subset) who have achieved disease control after 3 cycles

Acronym:

CUPISCO

ACTRN/NCT /ethics:

NCT03498521

Scientific title:

A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site

Sponsor / Cooperative group:

Hoffmann-La Roche